FFAR2 (Free Fatty Acid Receptor 2), also known as GPR43. is a G protein-coupled receptor that binds short-chain fatty acids (SCFAs) like acetate, propionate, and butyrate, which are produced by gut microbiota through dietary fiber fermentation. It plays a critical role in immune regulation, metabolic homeostasis, and gut-brain axis communication. FFAR2 is highly expressed in immune cells (e.g., neutrophils, macrophages), intestinal epithelial cells, and adipose tissue, where it modulates inflammatory responses, insulin secretion, and energy metabolism.
Antibodies targeting FFAR2 are essential tools for studying its expression, localization, and signaling mechanisms. They enable researchers to investigate its dual coupling to Gαi/o (inhibiting cAMP) and Gαq (activating intracellular calcium), as well as its role in diseases like inflammatory bowel disease (IBD), obesity, and diabetes. FFAR2 agonists or antagonists are explored for therapeutic potential, but selective antibodies help dissect receptor-specific effects in complex pathways. Challenges include ensuring specificity due to homology with FFAR3 (GPR41). Current research leverages FFAR2 antibodies in immunoassays, flow cytometry, and immunohistochemistry to unravel its tissue-specific functions and microbiota-host interactions, highlighting its relevance in precision medicine and metabolic disorder therapeutics.